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ABSTRACT 
Background Racial/ethnic minority patients are less likely than non-Latino white patients 
to participate in cancer clinical trials. A key barrier to participation is limited health 
literacy which is more common among minorities. At the organizational level, it is 
important that clinical trials sites become better equipped to recruit minority patients by 
expanding their organizational health literacy including language competency and 
outreach efforts. We explored the characteristics of clinical trial sites that are associated 
with these health literate behaviors. 
Methods We identified 353 breast clinical trials recruiting participants in 2006 from four 
states (California, Florida, Illinois, and New York) through the National Cancer Institute 
Physician Data Query system. From October 2008 to November 2009, we contacted one 
research team member (RTM) from each site for a telephone survey to assess the site’s 
health literate characteristics. 
Results Of 233 RTMs who responded, 93% were female and 89% were US-born. 
Overall, 48% of sites offered supplementary trial information, 80% offered materials to 
assist with patient navigation and 45% reported outreach efforts. Lower percentages 
offered information in other languages while 65% offered professional interpretation 
services. Sites with >10% limited English proficiency (LEP) patients were more likely 
than their counterparts to offer consent forms (OR=3.13, 1.36-7.19) and supplementary 
information about trials in other languages (OR=2.52, 1.15-5.52). Sites with diverse 
patient populations (>10% Latino) were also more likely than less diverse sites to engage 
in outreach (OR=1.97, 1.07-3.60), to offer consent forms (OR=2.72, 1.38-5.36), 
supplementary information about trials (OR=2.58, 1.24-5.36), and materials to improve 
patient navigation (OR=2.50, 1.22-5.13) in other languages. 
Conclusions Efforts to recruit diverse participants were limited. Practice type and 
diversity of patient population were associated with sites’ efforts to accommodate these 
characteristics, suggesting that sites were responsive to the needs of their patients when 
diversity was prevalent. 
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INTRODUCTION 
Clinical trials provide the foundation for advances in cancer diagnostics and therapeutics 
and are the major channel for translating treatment-related discoveries in breast cancer care into 
clinical practice (Ford et al., 1990). Clinical trials provide a high standard of medical care and 
help to generate new information that helps future patients (American Society of Clinical 
Oncology, 2012). To ensure that the benefits and burdens of this research are distributed fairly 
among all breast cancer patients, it is important that minorities participate. However, despite 
recent efforts to increase the participation of African Americans and Latinos in cancer clinical 
trials (Alexander et al., 2000; G. Corbie-Smith et al., 2003; Ness et al., 1997; Tejeda et al., 
1996), their enrollment remains lower than that of non-Latino Whites (Murthy et al., 2004).  
Reasons for lower rates of minority participation in clinical trials are multifaceted and 
may be explained by past experiences of minority patients with medical research resulting in 
negative attitudes toward clinical trials due to historical discrimination (Giselle Corbie-Smith et 
al., 1999; Kaluzny et al., 1993; Snow, 1993). Limited health literacy and limited English 
proficiency (LEP) are other key barriers to clinical trial recruitment (Joseph et al., 2009; Lloyd et 
al., 2008), and minorities disproportionally have limited health literacy and are of LEP (National 
Center for Education Statistics, 2006).  
In addition, physician characteristics such as specialty and amount of time spent in 
patient care impact clinical trial discussions, referral, and recruitment (Nguyen et al., 2005; 
Siminoff et al., 2000). A review of the provider’s role in clinical trial participation suggests that 
lack of physician awareness of clinical trials is a barrier to enrolling patients. Patient accrual is 
also negatively affected by physicians’  attitudes towards patient adherence to the study protocol, 
patient mistrust of research, and patient costs (Howerton et al., 2007). At the organizational 
level, lower rates of clinical trial participation among minorities can be in part attributed to the 
health care system failing to address  these patients’ informational needs at appropriate language 
and health literacy levels (Paasche-Orlow et al., 2007). This becomes especially apparent when 
assessing communication capabilities of the clinical trial site, e.g. the healthcare organization’s 
ability to provide linguistically appropriate and accessible information.  
Given the number and complexity of available cancer clinical trials, it can be difficult for 
patients, particularly minorities, those with limited health literacy and those of LEP, to determine 
their potential eligibility which, by extension, limits their participation in trials. Patients often 
struggle to understand and make decisions about research participation in the face of life-
threatening illness, multiple treatment options, and long-term physical, psychological, and 
logistical concerns. In addition, not all facilities have bilingual personnel to assist with 
recruitment and retention (Giuliano et al., 2000), which may particularly affect Latinos for whom 
English is a second language (U.S. Department of Commerce Bureau of the Census, May 2001). 
Thus, addressing the challenges of limited health literacy and LEP populations represents a 
critical focus for advancing cancer trial participation among minorities and thus reducing health 
disparities. 
Recognizing this, the Institute of Medicine (IOM) has identified health literacy as an 
urgent national priority area, emphasizing the critical role of the health care system in addressing 
the needs of patients with limited health literacy (Brach et al., 2012).  The IOM has defined 
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“health literate organizations” as “institutions that support individuals in navigating the 
complexities of the health care system” (Brach et al., 2012).  The Health Literate Care Model is 
based on the principles of “Health Literacy Universal Precaution” developed by AHRQ (DeWalt 
et al., 2010). This model postulates the need for health care providers to approach all patients 
with the assumption that health information may not be fully understood (DeWalt et al., 2010), 
and incorporates recommendations to help health care systems reduce the complexity of medical 
care and ensure that patients are able to succeed in the health care environment.  
The Agency for Healthcare Research and Quality (AHRQ) developed a toolkit to assist 
organizations in becoming health literate (DeWalt et al., 2010), recognizing that health literacy-
related outcomes are a function of both patient and health care system characteristics (Paasche-
Orlow et al., 2006; Paasche-Orlow et al., 2007). This toolkit provides a framework for 
organizations to become more health literate (DeWalt et al., 2010), and suggests that language 
competency (both written and verbal communication) and outreach efforts by organization (e.g., 
the clinical trials sites) are key to creating a health literate organization that addresses the needs 
of minority and limited health literacy patients, particularly those with LEP. Little is known 
about the organizational characteristics that are associated with language competency and 
outreach efforts, and therefore likely to affect recruitment of minorities into clinical trials.  
  To extend the current state of knowledge in this area, our study explored the clinical trial 
site (organizational) characteristics (e.g., practice type, racial/ethnic diversity of patient 
population, language diversity of patient population and number of phase III trials offered) that 
were associated with health literate behaviors (e.g., language competency and outreach) among 
clinical trial sites in California, Florida, Illinois, and New York recruiting patients for breast 
cancer trials in 2006. 
 
METHODS 
As part of a Department of Defense-funded project, we identified 384 breast cancer 
clinical trials recruiting participants in 2006 from four states (California, Florida, Illinois, and 
New York) through the Physician Data Query (PDQ) from the National Cancer Institute website. 
These states were selected because of their large minority populations who were potentially 
eligible to participate in clinical trials. We identified all sites implementing these trials (n=353) 
and the research team members (RTMs) involved at each site. Trials were eligible for inclusion if 
they were: a) located in California, Florida, Illinois, or New York; b) conducted in 2006; c) 
related to breast cancer treatment; and d) funded by the National Institutes of Health (NIH) 
and/or a pharmaceutical company. General information about the clinical trials, as well as 
contact information for the sites where they were conducted was obtained from the PDQ. The 
websites of the involved institutions were also consulted to obtain more detailed contact 
information for the individuals involved in breast cancer clinical trials, hereafter referred to as 
RTMs.  
Research assistants contacted one RTM from each site to complete a brief phone survey 
from October 2008 through November 2009. The survey was also available by mail, fax, or 
email, depending on preference. Verbal informed consent was obtained prior to the survey. All 
procedures were approved by the Committee on Human Research at the University of California 
San Francisco. 
 
Measures 
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RTM characteristics 
RTMs were asked to report their gender, country of birth, job title (clinical 
manager/coordinator, nurse, director/investigator, data manager/administrative personnel), and 
whether or not they spoke a language other than English.  
Clinical trial site characteristics 
RTMs were asked to describe their organization (e.g., practice type), and responses were 
grouped as follows; a) solo or group practice, b) public community health center/public hospital, 
c) VA, private or community based hospital, or d) University/medical school based 
practice/research or cancer institute. RTMs were also asked to estimate the percentages of their 
breast cancer patients who were Latina, Black or African American and had limited ability to 
communicate in English (limited English proficiency – LEP). These percentages were assessed 
continuously and dichotomized as ≥10% vs. <10%. For each site, we also obtained information 
on the number of phase III trials currently being conducted (responses were dichotomized into 
≥3 vs. <3).  
Health literate characteristics 
Communication (written and verbal), and outreach efforts were assessed to capture the 
health literate characteristics of each trial site. We asked RTMs to report the availability, overall 
and in languages other than English, of consent forms, summaries of studies, frequently asked 
questions (FAQ) sheets about studies, directions to study site and appointment reminder cards. 
We also asked about the availability of professional interpreter services and whether the sites 
gave outreach presentations to community, social and service groups and churches and 
participated in community health fairs or cancer awareness days to recruit patients.  
Communication (written) 
Consent documents. Respondents were asked whether printed consent documents were 
available to patients in languages other than English (yes or no).  
Supplementary information about clinical trials. Respondents were asked to indicate 
whether their organizations provided summaries of clinical trials and frequently asked questions 
(FAQ) sheets to patients overall (yes or no) and in a language other than English (yes or no). In 
both instances, if a respondent answered yes to both questions (e.g., summaries and FAQ sheets), 
their site was considered to offer supplementary information about clinical trials (overall or in 
other languages) 
Materials to facilitate recruitment into clinical trials. Respondents were asked to indicate 
whether their organizations provided directions to the study site or appointment reminder cards 
to patients overall (yes or no) and in a language other than English (yes or no). If a respondent 
answered yes to either of these questions (e.g., directions or appointment reminder cards), their 
site was considered to offer materials to improve patients’ navigation into clinical trials (overall 
or in other languages).  
Communication (verbal) 
Professional interpretation services. Those sites offering professional onsite interpreters, 
professional interpreter services by telephone, or professional video interpreter services were 
considered to have professional interpretation services available.  
Outreach 
Outreach efforts. Respondents were asked about their sites’ general recruitment 
strategies, including: presentations to community, social service groups, and churches and 
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participation in community health fairs or cancer awareness days. If a respondent answered yes 
to both of these recruitment strategies, their site was considered to engage in outreach efforts. 
Analysis 
Descriptive statistics were used to profile RTM characteristics, clinical trial site 
characteristics and health literate characteristics of the sites. We explored associations between 
individual clinical trial site characteristics (e.g., practice type, number of phase III trials, ≥10% 
Latina patients, ≥10% African American patients and ≥10% LEP patients) and health literate 
characteristics (e.g., communication and outreach). For each association, we used logistic 
regression analysis to estimate odds ratios [OR] and 95% confidence intervals [CI] and 
conducted all analyses in Stata Version 11.2. All comparisons were adjusted for state and 
practice type (with the exception of the practice type analyses which were adjusted only for 
state).  
  
RESULTS 
Sample characteristics. Of the initial 353 clinical trials sites selected, 85 were ineligible 
(68 sites were excluded because they had the same staff and practices as another site that had 
already completed the survey, 7 sites no longer conducted clinical trials, 1 was under new 
management, 4 did not enroll breast cancer patients, and 5 never participated in clinical trials).  
The remaining 268 were contacted for interviews. Twenty-two sites refused to participate, four 
no longer employed RTMs and nine were never reached. This yielded 233 completed interviews 
for a response rate of 87%.  
Descriptive analysis  
RTM characteristics. The majority of RTM respondents were female and born in the 
United States (see Table 1). More than half of respondents identified themselves as the clinical 
manager or clinical coordinator at their site, while 24% were nurses, 10% identified themselves 
as the Director or a trial Investigator and 10% identified themselves as the data manager or 
administrative personnel. Approximately one-quarter of respondents spoke another language in 
addition to English.  
Clinical trial site characteristics. Thirty-seven percent of trial sites were located in 
California, 23% in New York, 20% in Illinois and 20% in Florida (see Table 1). The majority of 
sites were solo or group practices, while more than one-quarter were public or community health 
centers or hospitals, 20% were university or teaching hospitals or research/cancer institutes and 
less than 10% were VA, private or community hospitals. On average, sites reported that 13% of 
their breast cancer patients were African American, 15% were Latina, and 8% were LEP. Just 
over half of the sites had 3 or more Phase III trials underway.  
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Table 1. Research team member (RTM) and clinical trial site 
characteristics (N=233) 
 n %
a
 
RTM Characteristics    
Female 215 (92.7) 
Born in the U.S. 201 (88.6) 
Job title   
Clinical manager/coordinator 131 (56.5) 
Nurse 55 (23.7) 
Director/Investigator 22 (9.5) 
Data manager/administrative personnel 24 (10.3) 
Speaks another language 60 (25.9) 
Clinical trial site characteristics   
State   
California  87 (37.3) 
Illinois 47 (20.1) 
New York 53 (22.8) 
Florida  46 (19.7) 
Type of Practice   
Solo or group practice 105 (45.1) 
Public community health center/hospital 63 (27.0) 
VA, private or community hospital 21 (9.0) 
University/teaching hosp/research or cancer institute 44 (18.9) 
Patient population   
% African American (mean ± SD) 12.5 ± 16.1 
% Latinos (mean ± SD) 15.2 ± 18.2 
% with limited English proficiency (mean ± SD)   8.4 ± 14.4 
Number of Phase III Clinical trials  
≤2 111 (47.6) 
≥3 122 (52.4) 
a
Percentages based on non-missing values  
  
Health literate characteristics. Seventy-two percent of sites offered consent documents in 
languages other than English (see Table 2). Slightly less than half of sites (48%) offered 
supplemental information about clinical trials, including both summaries of studies and FAQ 
sheets, and only 22% offered these materials in languages other than English. While the majority 
of sites (80%) offered materials to facilitate recruitment into clinical trials (directions to study 
site or appointment reminder cards), only 26% offered either of these materials in other 
languages. Sixty-five percent of sites offered professional interpretation services. Less than half 
of sites engaged in outreach efforts including both presentations to community, social and 
service groups and churches and participation in community health fairs or cancer awareness 
days.  
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Table 2. Health Literate Characteristics of Clinical Trial Sites (N=233)  
 
Available for 
English-
speaking 
patients 
Available for 
non-English-
speaking 
patients  
 n (%) n (%) 
COMMMUNICATION (WRITTEN AND VERBAL)   
Consent forms 23 (100) 167 (71.7) 
Supplementary information about clinical trials (both types 
available) 112 (48.1) 52 (22.3) 
Summaries of studies 153 (65.7) 78 (33.5) 
Frequently asked questions sheets about studies 144 (61.8) 79 (33.9) 
Any materials to facilitate recruitment into clinical trials  186 (79.8) 61 (26.3) 
Directions to study site 105 (45.1) 39 (16.8) 
Appointment reminder cards 161 (69.1) 41 (17.6) 
Professional interpretation services   n/a 151 (64.8) 
OUTREACH   
Outreach efforts (both types used) 105 (45.1) n/a  
Presentations to community, social and service groups, churches 117 (50.2) n/a 
Participation in community health fairs or cancer awareness days  160 (68.7) n/a 
 
 
Multivariable analyses 
Health literate characteristics (overall) (Table 3)  
Supplementary information about clinical trials. None of the clinical trial site 
characteristics we explored were significantly associated with offering supplementary 
information about clinical trials (summaries of studies and FAQs)  
Materials to facilitate recruitment into clinical trials. Compared to solo or group practice 
sites, sites within public or community health centers or hospitals (OR=0.28, 0.13-0.64), and 
VA, private or community hospitals (OR=0.29, 0.09-0.94) were less likely to offer materials to 
improve patient navigation to trials. Trial sites with patient populations of ≥10% LEP were also 
less likely to offer these materials (OR=0.46, 0.21-0.99).  
Outreach efforts. Compared to solo or group practice sites, university/teaching hospitals 
and research/cancer institutes were more likely to engage in outreach efforts (OR=2.20. 1.03-
4.70), as were sites with patient populations of ≥10% Latina compared to their counterparts 
(OR=1.97, 1.07-3.60).  
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Table 3. Adjusted Odds Ratios: Availability of services according to site characteristics (n=233) 
 
 
COMMUNICATION 
(Written) 
 
 
OUTREACH 
 
 
Supplementary information  
about clinical trials  
Any materials to facilitate 
recruitment into clinical 
trials 
 
 
Outreach efforts  
 OR (95% CI) OR (95% CI) OR (95% CI) 
Type of practice
a
     
Solo or group practice  ref ref ref 
Public community health 
center/hospital 1.02 (0.54-1.92) 0.28 (0.13-0.64)² 1.80 (0.91-3.29) 
VA, private or community 
hospital 0.60 (0.22-1.60) 0.29 (0.09-0.94)³ 1.19 (0.44-3.22) 
University/teaching 
hosp/research or cancer 
institute 0.66 (0.31-1.40) 0.40 (0.15-1.07) 2.20 (1.03-4.70)³ 
Number of phase III clinical trials
b
    
≤ 2 phase III trials  ref ref ref 
≥3 phase III trials 1.55 (0.90-2.66) 1.43 (0.73-2.83) 1.07 (0.62-1.85) 
Percent of Latinas in patient population
b
    
<10%  ref ref ref 
≥10%  1.64 (0.91-2.96) 0.99 (0.47-2.07) 1.97 (1.07-3.60)³ 
Percent of African Americans in patient population
b
   
<10%  ref ref ref 
≥10%  1.10 (0.62-1.96) 1.33 (0.63-2.81) 1.04 (0.58-1.86) 
Percent of patients who are LEP
b
    
<10%  ref ref ref 
≥10%  1.37 (0.72-2.62) 0.46 (0.21-0.99)³ 1.42 (0.74-2.73) 
          a 
Analyses adjusted for state 
          b 
Analyses adjusted for state and practice type 
        ¹p<0.05; ²p<0.01; ³p<0.05  
 
Health literate characteristics (services available in other languages) (Table 4) 
Consent forms in other languages. Trial sites with patient populations of ≥10% Latina 
and ≥10% LEP were more likely than their counterparts to provide consent forms in other 
languages (OR= 2.49, 1.28-4.85 and OR=3.13, 1.36-7.19 respectively).   
Supplemental information about clinical trials in other languages. Trial sites with patient 
populations of ≥10% Latina and ≥10% LEP were more likely than their counterparts to offer 
supplemental information about clinical trials in other languages (OR=2.58, 1.24-5.36 and 
OR=2.52, 1.15-5.52 respectively).  
Materials to facilitate recruitment into clinical trials, in other languages. Trial sites with 
patient populations of ≥10% Latina were more likely than their counterparts to offer materials in 
other languages to improve access to care (OR=2.50, 1.22-5.13).  
Professional interpretation services available. Compared to solo or group practice sites, 
sites within public or community health centers or hospitals (OR=7.45, 3.32-16.8), VA, private 
or community hospitals (OR=3.59, 1.20-10.7) and university/teaching hospitals and 
research/cancer institutes (OR=4.22, 1.81-9.87) were more likely to provide professional 
interpretation services.  
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Table 4. Adjusted Odds Ratios: Availability of services in other languages, according to site characteristics 
(n=233) 
 COMMUNICATION 
  (Written) (Written)  (Written)  (Verbal) 
 
Consent forms in 
other languages 
Supplementary 
information about 
clinical trials, in other 
languages 
Any materials to 
facilitate recruitment 
into clinical trials, in 
other languages 
Professional 
interpretation 
services 
 OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) 
Type of practice
a
        
Solo or group practice  ref ref ref ref 
Public community 
health center/hospital 0.76 (0.38-1.52) 
 
1.49 (0.70-3.18) 0.96 (0.46-2.03) 7.45 (3.32-16.8)¹ 
VA, private or 
community hospital 0.70 (0.25-1.90) 
 
0.99 (0.25-3.94) 1.45 (0.49-4.31) 3.59 (1.20-10.7)³ 
University/teaching 
hosp/research or 
cancer institute 1.11 (0.47-2.58) 
 
 
1.35 (0.54-3.37) 1.14 (0.50-2.64) 4.22 (1.81-9.87)² 
Number of phase III clinical trials
b
     
≤ 2 phase III trials 
(ref) ref 
 
ref ref ref 
≥3 phase III trials 0.70 (0.39-1.27) 1.05 (0.54-2.04) 0.82 (0.45-1.51) 1.79 (0.98-3.28) 
Percent of Latinas in patient population
b
     
<10% (ref) ref ref ref ref 
≥10%  2.49 (1.28-4.85)² 2.58 (1.24-5.36)³ 2.50 (1.22-5.13)³ 1.83 (0.93-3.62) 
Percent of patients who are LEP
b
     
<10% (ref) ref ref ref ref 
≥10%  3.13 (1.36-7.19)² 2.52 (1.15-5.52)³ 2.02 (0.98-4.13) 1.99 (0.92-4.30) 
a 
Analyses adjusted for state 
b 
Analyses adjusted for state and practice type 
¹p<0.05; ²p<0.01; ³p<0.05  
 
DISCUSSION 
Patient and physician-level barriers to recruitment of minority patients into clinical trials 
have been well described but less is known about the organizational characteristics that are 
associated with language competency and outreach efforts, and therefore likely to affect 
recruitment of minorities into clinical trials. Characteristics of the clinical trial environment can 
influence whether or not minority, LEP, and limited health literacy patients participate in cancer 
clinical trials (Brach et al., 2012). As recognized by the Agency for Healthcare Research and 
Quality (AHRQ), language competency (written and verbal) and outreach efforts by clinical trial 
sites are necessary components for creating health literate organizations that are equipped to 
address the needs of minority and limited health literacy patients (DeWalt et al., 2010). The lack 
of language competency and outreach to these patients on the part of cancer clinical trial sites 
may explain in part the lower rates of trial participation documented in these groups (Alexander 
et al., 2000; G. Corbie-Smith et al., 2003; Murthy et al., 2004; Ness et al., 1997; Tejeda et al., 
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1996). Overall, the clinical trial sites we examined made limited efforts to recruit ethnically and 
linguistically diverse participants.  
Information transfer within the informed consent process and full disclosure of 
information regarding content and delivery of treatment in a clinical trial are believed to be 
important predictors of recruitment of patients into trials (Wright et al., 2002). While the 
majority of clinical trial sites offered consent forms to patients in languages other than English , 
consent forms are considered difficult to understand and interpret (Cornett, 2009; Davis et al., 
2002; Lorenzen et al., 2008) and may not sufficiently enable patients to make informed decisions 
about participation. Offering materials that provide supplemental information about clinical trials 
can be essential to encouraging participation. Short summaries of trials and FAQ sheets may 
assist in making consent forms more comprehensible, allowing patients to make fully informed 
decisions about participation (Institute, 2013). However, less than half of sites offered any 
supplemental materials to patients, and even fewer offered these materials in languages other 
than English.  Of note, language competency, including the availability in other languages of 
consent forms and supplementary information about clinical trials, was greatest among sites 
serving diverse populations with large proportions of Latinos and LEP patients. The increased 
availability of short summaries and FAQ documents in other languages at sites with more diverse 
populations suggests that these sites are responding to the needs of their patient populations (e.g., 
Latinas and LEP patients) by providing materials in other languages.  
While most sites offered materials including directions to the study site and appointment 
reminders to facilitate patients’ navigation to clinical trials, hospitals were less likely to do so 
than solo practices, as were sites with ≥10% LEP patients. In addition, very few sites offered 
these materials in other languages. However, our results suggest that if these materials were 
available at a site, those sites with more LEP patients were more likely to offer the materials in 
other languages.  
The use of professional interpretation services among LEP patients is associated with 
improved quality of clinical care (Flores, 2005; Karliner et al., 2007), and is also likely to 
facilitate recruitment of these patients into clinical trials. However, less than two-thirds of 
clinical trial sites offered professional interpretation services. Solo and group practices were less 
likely than other sites to do so. Resources available to larger institutions may partially explain the 
discrepancy. With larger patient populations, the cost-effectiveness of interpretation services 
may be greater due to economies of scale or shared resources across sites. In addition, the federal 
government mandates health care providers who receive federal funding to provide language 
interpretation services to their LEP patients (Blanchfield et al., 2011; Jacobs et al., 2006) and 
larger institutions may be more likely to receive federal funding. Another potential explanation is 
that solo and group practices had the least diverse patient populations in our study.  
Outreach efforts are also a critical component of recruiting clinical trial participants, 
particularly for difficult-to-reach populations including racial/ethnic minorities and those with 
limited health literacy. Less than half of the clinical trial sites we studied engaged in community 
outreach. University/teaching hospitals and research or cancer institutes were more likely than 
solo or group practices to engage in outreach, as they may have been better equipped to do so, 
given greater resources. Sites with more diverse patient populations were also more likely to 
engage in outreach efforts. The latter finding provides further evidence that sites appear to be 
responding to the needs of their patient populations by engaging in outreach efforts to target 
difficult-to-reach individuals (e.g., Latinas).  
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 Several limitations to our study are worth noting. We were not able to interview RTMs 
from all sites identified. If site characteristics differed between RTM respondents and non-
respondents, our findings may not be generalizable. Findings may also not be representative of 
practices or behaviors in less diverse areas of the country since we selected trials conducted in 
states with large minority populations. Language competency may be even poorer in less diverse 
areas of the country. We did not assess the quality of materials translated into other languages or 
their literacy level. Thus, the supplementary information provided about clinical trials may have 
been written at a high literacy level. In addition, we relied on key informant RTMs from each 
clinical trial site to answer questions about language competency and outreach. It is possible that 
the person interviewed might not have had all of the necessary information to answer these 
questions. However, we attempted to interview RTMs who were intimately involved in all 
aspects of the clinical trials being conducted at their site.  
Finally, data were cross sectional. As a result, we are unable to establish whether clinical 
trial site characteristics influenced the patient population served, or whether trial sites adapted 
their recruitment efforts to fit the needs of their specific patient population. Sites that do not 
serve many LEP patients may have limited incentives or demand to provide patient materials and 
study information in other languages. However, if these sites were to improve their language 
competency, perhaps they would attract more culturally and linguistically diverse patients.  
 
 
CONCLUSION 
Language competency is an elemental characteristic of health literate organizations. 
Without language appropriate materials or professional interpreter services, clinical trials sites 
rely on ad hoc interpretation that may be imprecise and misleading. Improving cultural and 
language competency is a desirable goal that can be strived for and potentially achieved by most 
clinical trial sites. The failure to do so undermines the clinical trial site’s outreach and 
recruitment efficacy and further undercuts national efforts to diversify the pool of clinical trial 
participants (e.g. ENACCT, IMPACT, etc.). Our study identifies gaps in language competency 
and outreach efforts at the organizational level, and therefore, gaps in responsiveness to the most 
basic health literacy needs of patient populations at clinical trial sites across the United States.  
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